MARKET

PBM

PBM

Psyence Biomedical Ltd.
NASDAQ
0.8589
+0.0192
+2.29%
After Hours: 0.8873 +0.0284 +3.31% 19:54 04/26 EDT
OPEN
0.8206
PREV CLOSE
0.8397
HIGH
0.8840
LOW
0.8100
VOLUME
86.55K
TURNOVER
0
52 WEEK HIGH
14.55
52 WEEK LOW
0.5135
MARKET CAP
11.50M
P/E (TTM)
-19.4321
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PBM last week (0415-0419)?
Weekly Report · 5d ago
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Benzinga's psychedelic headlines roundup includes a look at the first two weeks of April 2024. Psilocybin could alter mechanisms associated with major depression and neurodegenerative diseases. Ancient Romans used to trip on hallucinogenic plants, archeologists say. Psycon's 2024 edition will take place in Colorado in May.
Benzinga · 04/17 13:13
Psyence Biomed Announces Phase IIb Clinical Trial Listing On The Australian New Zealand Clinical Trials Registry
Psyence Biomed's upcoming Phase IIb clinical trial of nature-derived psilocybin in patients diagnosed with Adjustment Disorder following an advanced cancer diagnosis has been listed on the Australian New Zealand Clinical Trials Registry. The randomized, double-blind, placebo-controlled study will test 84 patients in conjunction with psychotherapy. The Company anticipates enrolling the first subject in the second quarter of 2024.
Benzinga · 04/17 12:01
PSYENCE BIOMEDICAL LTD: ANTICIPATES ENROLLING FIRST SUBJECT IN Q2 OF 2024 AND EXPECTS PRIMARY ENDPOINT RESULTS TO BE AVAILABLE IN 2025
Reuters · 04/17 12:00
PSYENCE BIOMED ANNOUNCES PHASE IIB CLINICAL TRIAL LISTING ON THE AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY (ANZCTR)
Reuters · 04/17 12:00
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Psyence Group Inc is a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing. Psyence Australia has entered into a partnership with Fluence to support an upcoming Phase llb clinical trial. The company's Australian subsidiary is a subsidiary of Psyence Group.
Barchart · 04/16 10:01
Weekly Report: what happened at PBM last week (0408-0412)?
Weekly Report · 04/15 11:48
PSYENCE BIOMEDICAL LTD: EXPECTS PRIMARY ENDPOINT RESULTS TO BE AVAILABLE IN 2025 FOR DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE IIB STUDY
Reuters · 04/08 12:05
More
About PBM
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Webull offers Psyence Biomedical Ltd stock information, including NASDAQ: PBM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBM stock methods without spending real money on the virtual paper trading platform.